Pulmonary endothelial barrier dysfunction is a hallmark of clinical pulmonary edema and contributes to the development of acute lung injury(ALI).Here we reported that ruscogenin(RUS),an effective steroidal sapogenin o...Pulmonary endothelial barrier dysfunction is a hallmark of clinical pulmonary edema and contributes to the development of acute lung injury(ALI).Here we reported that ruscogenin(RUS),an effective steroidal sapogenin of Radix Ophiopogon japonicus,attenuated lipopolysaccharides(LPS)-induced pulmonary endothelial barrier disruption through mediating non-muscle myosin heavy chain IIA(NMMHC IIA)-Toll-like receptor 4(TLR4)interactions.By in vivo and in vitro experiments,we observed that RUS administration significantly ameliorated LPS-triggered pulmonary endothelial barrier dysfunction and ALI.Moreover,we identified that RUS directly targeted NMMHC IIA on its N-terminal and head domain by serial affinity chromatography,molecular docking,biolayer interferometry,and microscale thermophoresis analyses.Downregulation of endothelial NMMHC IIA expression in vivo and in vitro abolished the protective effect of RUS.It was also observed that NMMHC IIA was dissociated from TLR4 and then activating TLR4 downstream Src/vascular endothelial cadherin(VE-cadherin)signaling in pulmonary vascular endothelial cells after LPS treatment,which could be restored by RUS.Collectively,these findings provide pharmacological evidence showing that RUS attenuates LPS-induced pulmonary endothelial barrier dysfunction by inhibiting TLR4/Src/VE-cadherin pathway through targeting NMMHC IIA and mediating NMMHC IIA-TLR4 interactions.展开更多
基金supported by the National Natural Science Foundation of China(No.81773971,China)Double FirstClass University Project(No.CPU2018GF07,China)。
文摘Pulmonary endothelial barrier dysfunction is a hallmark of clinical pulmonary edema and contributes to the development of acute lung injury(ALI).Here we reported that ruscogenin(RUS),an effective steroidal sapogenin of Radix Ophiopogon japonicus,attenuated lipopolysaccharides(LPS)-induced pulmonary endothelial barrier disruption through mediating non-muscle myosin heavy chain IIA(NMMHC IIA)-Toll-like receptor 4(TLR4)interactions.By in vivo and in vitro experiments,we observed that RUS administration significantly ameliorated LPS-triggered pulmonary endothelial barrier dysfunction and ALI.Moreover,we identified that RUS directly targeted NMMHC IIA on its N-terminal and head domain by serial affinity chromatography,molecular docking,biolayer interferometry,and microscale thermophoresis analyses.Downregulation of endothelial NMMHC IIA expression in vivo and in vitro abolished the protective effect of RUS.It was also observed that NMMHC IIA was dissociated from TLR4 and then activating TLR4 downstream Src/vascular endothelial cadherin(VE-cadherin)signaling in pulmonary vascular endothelial cells after LPS treatment,which could be restored by RUS.Collectively,these findings provide pharmacological evidence showing that RUS attenuates LPS-induced pulmonary endothelial barrier dysfunction by inhibiting TLR4/Src/VE-cadherin pathway through targeting NMMHC IIA and mediating NMMHC IIA-TLR4 interactions.
